These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2934582)

  • 1. Hormonal effects of GnRH agonist in the human male: an approach to male contraception using combined androgen and GnRH agonist treatment.
    Swerdloff RS; Handelsman DJ; Bhasin S
    J Steroid Biochem; 1985 Nov; 23(5B):855-61. PubMed ID: 2934582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen.
    Bhasin S; Yuan QX; Steiner BS; Swerdloff RS
    J Clin Endocrinol Metab; 1987 Sep; 65(3):568-74. PubMed ID: 3114307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal effects of GnRH agonist in the human male: II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist.
    Bhasin S; Heber D; Steiner B; Peterson M; Blaisch B; Campfield LA; Swerdloff RS
    Clin Endocrinol (Oxf); 1984 Feb; 20(2):119-28. PubMed ID: 6232019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does constant infusion of gonadotropin-releasing hormone agonist lead to greater suppression of gonadal function in man than its intermittent administration?
    Bhasin S; Steiner B; Swerdloff R
    Fertil Steril; 1985 Jul; 44(1):96-101. PubMed ID: 3924670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin releasing hormone (GnRH) agonists in male contraception.
    Swerdloff RS; Steiner BS; Bhasin S
    Med Biol; 1986; 63(5-6):218-24. PubMed ID: 2939304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stimulatory and down-regulatory effects of a gonadotropin-releasing hormone agonist in man.
    Heber D; Bhasin S; Steiner B; Swerdloff RS
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1084-8. PubMed ID: 6233295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in the control of testicular function.
    Swerdloff RS; Wang C; Bhasin S
    Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone.
    Behre HM; Kliesch S; Lemcke B; von Eckardstein S; Nieschlag E
    Hum Reprod; 2001 Dec; 16(12):2570-7. PubMed ID: 11726576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study.
    Rosenfield RL; Perovic N; Ehrmann DA; Barnes RB
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3408-11. PubMed ID: 8784105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
    Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
    Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone.
    Pavlou SN; Interlandi JW; Wakefield G; Rivier J; Vale W; Rabin D
    J Androl; 1986; 7(4):228-33. PubMed ID: 3528106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.